![Valerie Odegard](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Valerie Odegard
Directeur/Membre du Conseil chez
ODYSSEY THERAPEUTICS, INC.
Fortune : - $ au 30/09/2026
Profil
Dr. Valerie Odegard is a Chief Executive Officer at Dovetail Therapeutics, Inc., a Venture Partner at OrbiMed Advisors Private Equity and an Independent Director at Odyssey Therapeutics, Inc. She is on the Board of Directors at Odyssey Therapeutics, Inc. and Abata Therapeutics, Inc. Dr. Odegard was previously employed as a President & Chief Scientific Officer by Silverback Therapeutics, Inc. and a Vice President-Research by Juno Therapeutics, Inc. She received her undergraduate degree from Wake Forest University and a doctorate degree from Yale University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 08/05/2026 | 0 ( -.--% ) | - $ | 30/09/2026 |
Postes actifs de Valerie Odegard
| Sociétés | Poste | Début |
|---|---|---|
| ODYSSEY THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/10/2021 |
Abata Therapeutics, Inc.
 Abata Therapeutics, Inc. BiotechnologyHealth Technology Engages in development of treg cell therapies for serious autoimmune and inflammatory diseases | Directeur/Membre du Conseil | 29/07/2021 |
OrbiMed Advisors Private Equity
 OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity invests in companies located across the globe primarily in North America, Asia, Europe and Israel. The firm focuses on biopharmaceuticals, medical technology and healthcare services. It participates in seed-stage, early stage, growth transactions. It also provides debt capital and monetize royalty streams and invests in publicly-traded companies. | Private Equity Investor | 01/10/2022 |
Anciens postes connus de Valerie Odegard
| Sociétés | Poste | Fin |
|---|---|---|
| ARS PHARMACEUTICALS, INC. | President | 02/09/2022 |
| JUNO THERAPEUTICS INC | Directeur Technique/Scientifique/R&D | 01/10/2016 |
Formation de Valerie Odegard
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
64
Relations au 1er degré
7
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Wake Forest University
 Wake Forest University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity invests in companies located across the globe primarily in North America, Asia, Europe and Israel. The firm focuses on biopharmaceuticals, medical technology and healthcare services. It participates in seed-stage, early stage, growth transactions. It also provides debt capital and monetize royalty streams and invests in publicly-traded companies. | Finance |
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company to treat cancer, HIV and cardiovascular diseases | Health Technology |
Silverback Therapeutics, Inc.
 Silverback Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
Odyssey Therapeutics, Inc.
 Odyssey Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops therapeutics for autoimmune and inflammatory diseases | Health Technology |
Abata Therapeutics, Inc.
Abata Therapeutics, Inc. BiotechnologyHealth Technology Engages in development of treg cell therapies for serious autoimmune and inflammatory diseases | Health Technology |
